Antialprenolol rabbit antibodies were fractionated on an acebutolol affinity resin, followed by L-propranolol elution so as to separate a class of binding sites that mimic the betaadrenergic receptor. Allotype-identicaL rabbits were immunized with this fraction. After 6 mo, antisera exhibited antiidiotypic activity inhibiting [3H]alprenolol binding to the original antibody and to rabbit antiacebutolol antibodies, which had a spectrum of ligand-binding properties identical to the original idiotype. Those antisera demonstrating the original idiotype. Those antisera demonstrating the most potent antiidiotypic activity also blocked [3H]alprenolol binding to the beta-adrenergic receptor of turkey membrane, canine pulmonary membrane, and rat reticulocyte. An idiotype affinity-purified fraction showed similar activity, inhibiting beta-receptor binding with a calculated dissociation constant (KD) of 53 nM. Isoproterenol-mediated adenylate cyclase activity was also inhibited in a competitive manner. The universality of recognition of these antiidiotypic antisera indicate that the three-dimensional structure of a receptor's binding site can be modeled by a subset of an elicited antibody population. 
INTRODUCTION
Elicited antibodies to the f,-adrenergic antagonist alprenolol display binding characteristics similar to the ,8-receptor itself (1, 2) . The remarkable characteristics of this antialprenolol antibody population include a binding affinity in the nanomolar range and general recognition of ,B-agonists. Moreover, we have previously shown that by taking advantage of affinity purification procedures in conjunction with ligand-specific elution, it is possible to separate a class of antibody binding sites that demonstrate stereospecific recognition properties (2) . We had suggested that this affinityfractionated antibody population could be used as an antigen for the production of antiidiotypic antibodies that might also interact with a similarly structured binding site within the ,B-adrenergic receptor itself. Such an approach has already been successfully applied with insulin, a far more complex ligand than alprenolol, in the identification of insulin receptors on cell membranes (3). More recently, Schreiber et al. (4) have also reported on the development of antiidiotypic antibodies that recognize the ,-receptor. Important contrasts between our results are evident. The antireceptor activity of our antiserum behaves as a classic competitive antagonist of the receptor in contrast to the findings of this group. Furthermore, we have directly assessed the stoichiometry of the idiotype-antiidiotype interaction in an attempt to quantitate the fraction complementary to the ligand-binding site. These findings more clearly outline the utility of this approach as a general method for raising antibodies directed against the binding site of a cellular receptor. Assays. Antibody binding of ligand was determined by a double antibody precipitation assay as previously described (2) . In receptor assays, separation of bound from free ligand was achieved by vacuum filtration onto GFC glass filters as previously described (5) .
METHODS
The adenylate cyclase assay was performed as previously described (6) 
Syntheses
Ligand-protein complexes. Acebutolol amine was diazotized as previously described (9) and reacted directly with albumin in 10% Na2CO3 buffer. This was then extensively dialyzed against 50 mM Tris buffer, pH 7.4. Alprenolol-albumin was synthesized as previously described (2) .
Agarose-ligand resins. 3-Iminobispropylamine was attached to agarose utilizing CNBr activation as described by Cuatrecasas (10) using 60 ml Sepharose 4B, 11.0 g CNBr, and 13.1 g of iminobispropylamine. p-Hydroxy-phenylacetic acid (200 ,umol) was coupled to the resulting agarose amine (10 ml) using 0.1 M water-soluble 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide HCI in 20.0 ml H20 at pH 4.75 (maintained with 2 N HCI) for 1 h. The ninhydrin test showed the reaction to be complete. Acebutolol amine (200 umol) was then diazotized in 1.0 N HCI and 0.5 M NaNO2 for 10 min, after which it was added to the above resin that had been equilibrated in 10% Na2CO3.
Alprenolol-agarose was synthesized as previously described (2) . Each of these resins was substituted in the millimolar range as assessed by a direct radioimmunoassay (11) . Immunoadsorbent resins. Immunoglobulin (Ig) was coupled to CNBr-activated Sepharose directly in a 0.1 M NaHCO3 buffer, pH 8.3.
Ig and Fab preparation. The Ig was purified from 2.0 ml serum previously dialyzed into 10 mM phosphate buffer, pH 7.4, and 0.02% NaN3 by passage over a 20-ml DEAE cellulose column equilibrated in the same buffer. The Ig fraction was then eluted in the same buffer as confirmed by cellulose acetate electrophoresis. Fab was prepared by a modification of the method of Porter (12) .
Membrane preparation. Turkey erythrocyte membranes were prepared by a modification of the method of Lad et al. (13) from heparinized turkey blood. A last high-speed centrifugation was performed in 50 mM Tris buffer, pH 7.4. This resulted in a pellet with two distinct layers. The upper, whiter layer was swirled in buffer and removed from nuclear and mitochondrial debris. By phase-contrast microscopy this upper layer consisted principally of enucleated membrane ghosts. By Scatchard analysis these possessed 300-400 fmol 3-receptor/mg protein.
Canine lung was obtained from pentobarbital-anesthetized dogs. Hilar vessels, bronchi, and pleura were removed and the lung minced in 1 mM KHCO3, 0.25 M sucrose (5 vol) on ice and then homogenized in a Polytron (Brinkmann Instruments Inc., Westbury, NY) at a setting of 8 X 3 s then at setting 6 X 10 s. The material was then passed through two layers of silk screen and centrifuged at 2,000 rpm in a Sorvall RC-2-centrifuge (DuPont Instruments, Sorvall Biomedical Div., DuPont Co., Newtown, CT) for 10 min. The supernatant was then respun at 15,000 rpm for 20 min and the pellet resuspended to a concentration of 2-3 mg/ml in a 100 mM Tris, 5 mM EGTA, 1 mM MgCl2 buffer, pH 7.4. This preparation contained -100 fmol/mg membrane protein.
Rat reticulocytes were prepared as described by Wrenn and Homcy (9) . These preparations routinely contained -0.5-1.0 pmol receptor/mg protein.
Liver plasma membranes were prepared by a modification of the method of Song (14) and Ray (15) Saturation binding experiments were analyzed by the method of Scatchard (16) .
Immunization protocol. Rabbits were immunized with 0.5 mg of the protein-ligand complexes at 3-wk intervals in complete Freund's adjuvant by toepad injection. The protein-ligand complexes were shown by direct radioimmunoassay without preceding hydrolysis to be substituted at a 1:1 molar ratio. (2) . Those antibodies that recognized features common to the broad range of f-antagonists were purified by affinity fractionation. The antiserum was passed over an acebutolol-affinity resin and then eluted with L-propranolol. Such a procedure results in a class of antibodies that demonstrates stereospecificity in its recognition of f-ligands (2). The eluate was then extensively dialyzed and used for immunization as described.
Of eight rabbits initially immunized with 0.2-0.3 mg of affinity-purified antialprenolol antibody on a 3-4-wk schedule, the antiserum from one rabbit exhibited antiidiotypic activity after 2-3 mo. The assay was performed by incubating 25 Mul buffer, preimmune sera, or antiidiotypic antisera with either the original antiligand antibody, or with a membrane preparation when 13-receptor binding was analyzed in a total volume of 150 Ml. The double-antibody technique was used for the radioimmunoassay system and vacuum filtration for receptor assays to effect separation of bound from free ligand. The activity of an antiserum from a single bleeding at 24 wk after initial immunization demonstrating significant antiidiotypic and antireceptor activity is shown in Table I The antireceptor binding characteristics of this antiidiotypic antiserum were also assessed by saturation binding analysis using turkey erythrocyte membranes. At each point, total and nonspecific binding were determined in the presence of buffer, preimmune, or antiidiotypic antiserum in the same assay. As seen in Fig. 1A , the affinity constant and total receptor number are identical in the presence of preimmune sera or buffer, but the binding affinity is lower, approximately fourfold to 22 nM in the presence of antiidiotypic antiserum. In that receptor density appeared to be little changed, the antiserum behaved as a competitive inhibitor of receptor binding. Fig. lB 14 16 18 20 BOUND (fmo/) FIGURE 1 Effect of antiidiotypic antiserum on (3-receptor function as assessed by Scatchard analysis. Turkey erythrocyte membranes were incubated with increasing concentrations of (-)-[3Hlalprenolol, [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] Fig. 2 . Normal rabbit immunoglobulin at the highest concentration had no effect. The effects of this fraction on isoproterenolmediated adenylate cyclase stimulation in this same membrane preparation (Fig. 2) were studied at two different concentrations of isoproterenol, 0.5 ,uM, which is the apparent KD for cyclase stimulation in the turkey erythrocyte, and at a 200-fold higher concentration. At the lower isoproterenol concentration, significant inhibition occurs with most of this effect disappearing at the higher-saturating isoproterenol concentration. This finding is most consistent with competitive inhibition although the slight inhibition seen at 0.1 mM isoproterenol suggests a possible noncompetitive component as well.
The antiidiotypic titer in this rabbit antiserum was also assessed by a direct binding assay. A solid-phase technique was used in which affinity-purified antialprenolol Fab fragments were adsorbed to plastic wells. Antiidiotypic serum was then added at various dilutions and binding to the Fab fragment was detected by the use of iodinated protein-A, which should bind only to antiidiotypic antibodies adsorbed onto the Fab fragments. This technique provided a better measure of the antiidiotypic titer in that detection of binding was via a direct assay that did not depend on the inhibition of high-affinity ligand binding. As shown in Fig. 3 , this binding can be demonstrated at a 1:1,000-fold dilution of antiserum, which is clearly higher than that observed for antiidiotypic activity as detected by inhibition of [3H]alprenolol binding to the original antiligand antibody, or by inhibition of (3-receptor binding (cf . Table I ). Therefore, that fraction of this antiidiotypic response that was hapten inhibitable was also determined by this direct binding assay. Approximately 10% of the total binding at a 1:100-fold dilution of antiidiotypic antiserum is inhibited in the presence of a 1-,uM concentration of propranolol. To demonstrate that this inhibition was specific, the antiidiotypic antiserum was purified on an idiotypic affinity resin. Antialprenolol antibodies were first immobilized on agarose, and the antiidiotypic fraction was passed over the resin which was then extensively washed with 100 mM Tris buffer. The antiidiotypic antibodies were eluted with propranolol (1 mM) to obtain a purified subfraction that would compete with the ligand, propranolol, for binding to the original antiligand antibody. This purified antiidiotype was then itself iodinated and used in a solid-phase assay system. Plastic wells were first coated with purified antialprenolol antibodies, and then the iodinated, purified antiidiotypic antibodies were added in the presence or absence of 1 (3) reported the successful application of this general approach for developing antiidiotypic antibodies to the insulin receptor. However, high antiidiotypic antibody concentrations in the range of 2-3 mg/ml were required in their experiments to effect a 50% inhibition of insulin binding to its receptor and even higher concentrations to mimic its biologic effect. Schreiber et al. (4) used a similar approach in raising antibodies that recognized the fireceptor. These authors also used antialprenolol antibodies as the idiotype. However, DEAE purification alone was used to prepare an Ig fraction for their immunization protocol. Their immunogen would therefore have included unrelated antibodies and, in particular, would be expected to contain high titers of antialbumin antibodies in that an albumin-alprenolol complex had been used as the initial antigen. This contrasts with our approach in which an antibody population whose binding properties had first been refined by affinity fractionation was used for immunization. These differences may explain the variance in our results. Our antiidiotype behaved in a manner most consistent with competitive inhibition, determined both by saturation binding analysis and as assessed by isoproterenol-mediated adenylate cyclase activation. This contrasts with the results of Schreiber et al. (4) . By Scatchard analysis, their antibody displayed the characteristics of noncompetitive antagonism. In the presence of 5 mg/ml of antiidiotypic Ig, an '60% decrease in receptor number occurred with no change in affinity. Whether this is secondary to the action of the antibody at a site other than that which actually binds ligand or to its apparent intrinsic agonist activity is not clear. These studies indicate the suitability of using an elicited antibody response to obtain a population of binding sites whose properties mimic those of a ligand's biologic receptor. In particular, it was our aim to emphasize how a small ligand with a defined number of determinants may be the most appropriate system for such an approach. Suitability arises not only from the simplicity of the ligand's structure, but also from the ability to subfractionate antiligand antibodies by affinity techniques which allows the use of a library of available ligands with similar biologic activity but with different structural determinants. In our particular system, it appears that an additional factor that must be considered is the remarkable similarity in the characteristics of antibodies elicited to any of a variety of ,8-antagonists. All of these antiligand antibodies were also homologous to the biologic receptor in their binding properties, suggesting that conservation had occurred in the organism's recognition and response to this unique structure. Finally, the antiidiotypic response has been used to raise a population of binding site-directed antibodies. A small fraction of these recognize the three-dimensional structural homology between the antibody's binding site and that of the biologic receptor. However, due to the relatively low titer of these antibodies and the fleeting character of the response, the development of monoclonal antiidiotypic antibodies via somatic-cell hybridization techniques will be necessary before sufficient quantities can be produced to be routinely used as laboratory reagents. The potential specificity afforded by this immunologic approach may allow the development of anti-,8-receptor antibodies that possess not only high affinity for the binding site but also a degree of ,Bsubtype selectivity not available with synthetic ligands.
